Psoralen Alleviates Renal Fibrosis by Attenuating Inflammasome-Dependent NLRP3 Activation and Epithelial–Mesenchymal Transition in a Mouse Unilateral Ureteral Obstruction Model
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241713171 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tae Won Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon 51353, Republic of Korea. Hauptthemen laut MEDLINE: Ureteral Obstruction, Renal Insufficiency, Chronic, Furocoumarins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gyeongsang National University, Institute of Health Sciences of Gyeongsang National University.
Abstract (Originalsprache)
The role of psoralen (PS), a major active component extracted from Psoralea corylifolia L. seed, in renal fibrosis is still unclear. Thus, the objective of this study was to evaluate the effects of PS on the development and progression of renal fibrosis induced by unilateral ureteral obstruction (UUO) in a mouse model. Mice were divided into four groups: PS (20 mg/kg, i.g., n = 5), PS + sham (n = 5), UUO (n = 10), and PS + UUO (n = 10). PS was intragastrically administered 24 h before UUO and continued afterwards for 7 days. All mice were killed 7 days post UUO. Severe tubular atrophy, tubular injury, and tubulointerstitial fibrosis (TIF) were significantly developed in UUO mice. A higher expression of transforming growth factor-β1 (TGF-β1) was accompanied by elevated levels of α-smooth muscle actin (α-SMA) and phosphorylated Smad2/3 (pSmad2/3) at 7 days post UUO. However, PS treatment reduced tubular injury, interstitial fibrosis, and the expression levels of TGF-β1, α-SMA, and pSmad2/3. Furthermore, the levels of macrophages (represented by F4/80 positive cells) and the inflammasome, reflected by inflammasome markers such as nucleotide-binding and oligomerization domain-like receptors protein 3 (NLRP3) and cleaved caspase1 (cCASP-1), were significantly decreased by PS treatment. These results suggest that PS merits further exploration as a therapeutic agent in the management of chronic kidney disease (CKD).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon 51353, Republic of Korea.
- Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju 52828, Republic of Korea.
- Institute of Medical Science, Gyeongsang National University, Jinju 52828, Republic of Korea.
- Biomedical Research Institute, Gyeongsang National University Hospital, Jinju 52828, Republic of Korea.
ORCID-Profile: Jin Hyun Kim
Förderung
- Gyeongsang National University
- Institute of Health Sciences of Gyeongsang National University
Zitieren
APA
Lee, T. W., Bae, E., Kim, J. H., Jung, M. H., & Park, D. J. (2023). Psoralen Alleviates Renal Fibrosis by Attenuating Inflammasome-Dependent NLRP3 Activation and Epithelial–Mesenchymal Transition in a Mouse Unilateral Ureteral Obstruction Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713171
Vancouver
Lee TW, Bae E, Kim JH, Jung MH, Park DJ. Psoralen Alleviates Renal Fibrosis by Attenuating Inflammasome-Dependent NLRP3 Activation and Epithelial–Mesenchymal Transition in a Mouse Unilateral Ureteral Obstruction Model. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241713171
BibTeX
@article{Lee2023,
author = {Lee, Tae Won and Bae, Eunjin and Kim, Jin Hyun and Jung, Myeong Hee and Park, Dong Jun},
title = {Psoralen Alleviates Renal Fibrosis by Attenuating Inflammasome-Dependent NLRP3 Activation and Epithelial–Mesenchymal Transition in a Mouse Unilateral Ureteral Obstruction Model},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241713171}
}
EUVIMED